Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis
Table 1
In vitro activity of fosfomycin against aerobic and facultative Gram-negative bacteria.
Bacteria
Number tested
Fosfomycin
MIC50 (g/mL)
MIC90 (g/mL)
Range (g/mL)
Acinetobacter spp.
185
64–128
128–512
0.25–512
Citrobacter spp. (C. diversus and C. freundii)
251
1-2
4–16
0.03–128
Enterobacter spp. (E. agglomerans, E. aerogenes, and E. cloacae)
779
8–64
32–256
0.12–>512
Escherichia coli
9338
0.5–4
2–16
0.03–512
Escherichia coli ESBL-producing
362
0.5–2
2–32
0.03–512
Escherichia coli AmpC-producing
135
2
4–16
≤1–>512
Haemophilus influenzae
50
1
4
1–128
Klebsiella oxytoca
51
8
32
4–64
Klebsiella pneumoniae
392
16–32
32–>128
0.5–512
Klebsiella pneumoniae ESBL-producing
74
16
64
2–256
Klebsiella spp.
995
8–16
32–128
≤2–512
Morganella morganii
98
128–256
512
8–>512
Proteus mirabilis
1472
≤2–4
32–>128
≤1–>512
Proteus vulgaris (indole-positive Proteus)
341
≤2–16
8–256
≤2–256
Providencia spp. (P. rettgeri and P. stuartii)
164
2–16
8–128
≤2–512
Pseudomonas aeruginosa
1518
32–256
64–256
4–>512
Pseudomonas spp.
35
128
256
≤0.5–512
Serratia marcescens
307
8–16
16–128
≤2–128
Shigella spp.
185
2
2
0.5–64
Stenotrophomonas maltophilia
49
64
128
16–512
Data compiled from [9, 12, 32–41]. AmpC, chromosomal AmpC -lactamase; ESBL, extended-spectrum -lactamase. MIC50, minimum concentration (g/mL) required to inhibit the growth of 50% of isolates; MIC90, minimum concentration (g/mL) required to inhibit the growth of 90% of isolates.
